Last Updated:

Coronavirus: 'Three Vaccines At Clinical Trial Stage In India,' Says ICMR

In a major boost for the country's fights against Coronavirus, India currently has three vaccines in the clinical trial stage.

Coronavirus

In a major boost for the country's fights against Coronavirus, India currently has three vaccines in the clinical trial stage, said Professor Balram Bhargava, DG, ICMR. Union Health Minister Dr. Harsh Vardhan on Sunday had said that no date has been fixed for the launch of the vaccine in the country and it may be ready by the first quarter of next year.

The three vaccines that are in the clinical trial are -

  • COVAXIN, India's first indigenous vaccine against the SARS-CoV-2 virus developed by Bharat Biotech in partnership with ICMR.
  • The second vaccine on trial is the one by Serum Institute of India, Pune, which is manufacturing the vaccine developed by Oxford University, currently in phase 3 human trials.
  • The third vaccine candidate is by Zydus Cadila, is also in phases 1 and 2 trials.

READ: COVID-19 vaccine manufacturing has begun at a risk, will be ready by year-end: Pfizer CEO

'COVID Vaccine May Be Ready By The First Quarter Of Next Year'

Stating that the government is taking full precautions, the health minister interacted with his social media followers on the Sunday Samvad platform. He further said that the National Expert Group on Vaccine Administration for COVID-19 is drawing up a detailed strategy on how to immunize the majority of the population. Chairmanship of Dr. V K Paul, Member (Health), NITI Aayog is also extending its full support.

He said issues like vaccine security, cost, equity, cold-chain requirements, and production timelines are also being discussed intensely. Health Minister assured the vaccine will be first made available to those who need it the most, irrespective of their paying capacity. 

READ: 'Won’t be enough Covid vaccines for everyone till 2024': Serum Institute's Adar Poonawalla

COVID-19 Vaccine Update

Oxford University and Serum Institute of India's COVID-19 vaccine candidate being developed in collaboration with AstraZeneca pharmaceutical were halted after a volunteer developed an illness. On Saturday, Oxford University announced that the trials will be resumed while adding that with 18,000 test cases, some of the volunteers are bound to get unwell. In India, the vaccine trials haven't been resumed yet since the Drug Controller General of India (DCGI) order Serum Institute of India to halt trials and the recruitment of volunteers for the trials. While on the other hand, the COVID-19 vaccine candidate of Bharat Biotech 'Covaxin' had successful animal trials. 

READ: Bill Gates says world needs India's help for large-scale COVID-19 vaccine production

READ: China's coronavirus vaccines may be ready for use by November: Official

First Published: